Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus target price of $26.50 for the company and are predicting that the company will post ($0.33) EPS for the current quarter, according to Zacks. Zacks has also given Accelerate Diagnostics an industry rank of 109 out of 265 based on the ratings given to its competitors.

A number of equities research analysts have issued reports on AXDX shares. Zacks Investment Research cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. ValuEngine cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th.

In related news, Director Jack W. Schuler bought 5,500 shares of the business’s stock in a transaction on Friday, November 17th. The shares were bought at an average cost of $22.00 per share, for a total transaction of $121,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jack W. Schuler bought 20,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was bought at an average price of $20.00 per share, for a total transaction of $400,000.00. The disclosure for this purchase can be found here. Insiders acquired 981,667 shares of company stock worth $18,879,924 over the last quarter. 50.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. AXA lifted its stake in Accelerate Diagnostics by 40.2% in the third quarter. AXA now owns 432,647 shares of the medical research company’s stock valued at $9,713,000 after buying an additional 124,035 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Accelerate Diagnostics in the third quarter valued at $1,239,000. Jane Street Group LLC bought a new stake in shares of Accelerate Diagnostics during the third quarter valued at about $2,053,000. Schwab Charles Investment Management Inc. raised its stake in shares of Accelerate Diagnostics by 5.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 123,537 shares of the medical research company’s stock valued at $2,774,000 after purchasing an additional 6,301 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Accelerate Diagnostics during the third quarter valued at about $1,459,000. Institutional investors own 47.98% of the company’s stock.

Accelerate Diagnostics (AXDX) traded up $0.95 during trading on Wednesday, reaching $29.15. 869,819 shares of the company’s stock were exchanged, compared to its average volume of 634,002. Accelerate Diagnostics has a 1 year low of $16.75 and a 1 year high of $30.45.

COPYRIGHT VIOLATION NOTICE: “Zacks: Accelerate Diagnostics Inc (AXDX) Given Average Rating of “Strong Buy” by Analysts” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/09/zacks-accelerate-diagnostics-inc-axdx-given-average-rating-of-strong-buy-by-analysts.html.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Accelerate Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc and related stocks with our FREE daily email newsletter.